With the financing, Dennis Henner, PhD, Handling Director at Clarus Ventures, joined Aerie’s Table of Directors. Related StoriesAllergan completes acquisition of AqueSysEnvisia's ENV515 meets primary efficacy endpoint in phase 2a glaucoma trialAllergan enters into agreement to acquire Aquesys and its own XEN45 plan The more we learn about the unique, clinical great things about AR-12286, the more enthusiastic we are about its prospects while an differentiated and important glaucoma treatment, both seeing that monotherapy and in combination with existing glaucoma medications, said Dr. Henner. Aerie is a innovator in the field of ophthalmology with their portfolio of innovative glaucoma items, and we experience privileged to contribute to that success.Secondary-outcome values were log-transformed where suitable. Proportions were weighed against the use of Fisher’s exact test. Statistical software programs used for several analyses included SPSS, version 13 , Stata, edition 7 , and GraphPad Prism, version 4 . Outcomes Enrollment and Baseline Characteristics Figure 1Figure 1Numbers of Patients Who Had been Screened, Enrolled, and Assigned to a Study Group and Who Completed the Study. Shows the true amounts of topics who were screened, enrolled, and randomly assigned to a study group and who completed the study.